MAM
SNDX icon

Meeder Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Meeder Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-272
Closed -$5.24K – 1012
2024
Q3 		$5.24K Buy
272
+59
+28% +$1.22K ﹤0.01% 735
2024
Q2 		$4.37K Buy
213
+27
+15% +$565 ﹤0.01% 794
2024
Q1 		$4.43K Buy
+186
New +$4.15K ﹤0.01% 646
2020
Q3 		– Sell
-59
Closed – – 2359
2020
Q2 		$0 Sell
59
-901
-94% -$13.7K ﹤0.01% 2430
2020
Q1 		$11K Sell
960
-183
-16% -$1.72K ﹤0.01% 1484
2019
Q4 		$9K Buy
1,143
+520
+83% +$3.82K ﹤0.01% 1596
2019
Q3 		$5K Buy
623
+126
+25% +$1.15K ﹤0.01% 1776
2019
Q2 		$5K Buy
497
+246
+98% +$1.79K ﹤0.01% 1679
2019
Q1 		$1K Buy
+251
New +$1.43K ﹤0.01% 1641
2018
Q4 		– Sell
-202
Closed -$2K – 1793
2018
Q3 		$2K Buy
+202
New +$1.44K ﹤0.01% 1444
2018
Q2 		– Sell
-145
Closed -$2K – 1672
2018
Q1 		$2K Buy
+145
New +$1.54K ﹤0.01% 1393
2017
Q3 		– Sell
-219
Closed -$3K – 1751
2017
Q2 		$3K Sell
219
-3
-1% -$34 ﹤0.01% 1337
2017
Q1 		$3K Buy
222
+6
+3% +$62 ﹤0.01% 1278
2016
Q4 		$2K Buy
+216
New +$2.37K ﹤0.01% 937

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Meeder Asset Management's SNDX Position: Q4 2024 in Review

Meeder Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2024, closing a stake of 272 shares — an estimated $5.24K sold.

Meeder Asset Management first reported a position in SNDX in Q4 2016 and held it in 14 quarters. The position peaked at $11K in Q1 2020. 215 funds tracked by Wall St. Rank hold SNDX as of Q4 2024.

  • Meeder Asset Management reported no remaining Syndax Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Meeder Asset Management sold 272 Syndax Pharmaceuticals shares in Q4 2024, an estimated $5.24K.
  • Meeder Asset Management first reported a position in Syndax Pharmaceuticals in Q4 2016 and held it in 14 quarters.
  • Meeder Asset Management's Syndax Pharmaceuticals position peaked at $11K in Q1 2020.
  • 215 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2024.

Based on Meeder Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.